Investors nursing a fall in biotech indices now have to digest the failure of Bridgebio's acoramidis in 2021’s last important catalyst.
Explore what might be in store for biopharma next year in our new report, with new data analyses, catalyst tables and investor interviews.
This year has yet to see a blockbuster-style deal, but prices remain punchy nevertheless.
Aduhelm’s likely EU rejection comes amid a key senior executive departure and federal inquiry, and the drug now faces a crucial Medicare decision.
The group will get nearly $21bn for its Roche stake, and more if it sells Sandoz.
While Lilly has thrown in the tau towel with zagotenemab, Cortexyme still sees reasons to press on with atuzaginstat.
Lilly's remarkable decision to run a head-to-head trial of donanemab versus Aduhelm spells another big readout for the amyloid targeting space.
Astrazeneca’s Himalaya study is a surprising hit in first-line liver cancer, but competition is already present.